rs201042802

Variant summary

Our verdict is Benign. The variant received -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBS1BS2

The NM_004304.5(ALK):​c.2763C>T​(p.Phe921Phe) variant causes a synonymous change. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.00018 ( 0 hom., cov: 0)
Exomes 𝑓: 0.00016 ( 0 hom. )

Consequence

ALK
NM_004304.5 synonymous

Scores

2

Clinical Significance

Likely benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 4.85

Publications

10 publications found
Variant links:
Genes affected
ALK (HGNC:427): (ALK receptor tyrosine kinase) This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011]
ALK Gene-Disease associations (from GenCC):
  • neuroblastoma, susceptibility to, 3
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -18 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.3).
BP6
Variant 2-29228936-G-A is Benign according to our data. Variant chr2-29228936-G-A is described in ClinVar as Likely_benign. ClinVar VariationId is 538277.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.000177 (8/45154) while in subpopulation SAS AF = 0.00363 (4/1102). AF 95% confidence interval is 0.00124. There are 0 homozygotes in GnomAd4. There are 5 alleles in the male GnomAd4 subpopulation. Median coverage is 0. This position passed quality control check.
BS2
High AC in GnomAd4 at 8 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ALKNM_004304.5 linkc.2763C>T p.Phe921Phe synonymous_variant Exon 16 of 29 ENST00000389048.8 NP_004295.2
ALKXR_001738688.3 linkn.3668+22C>T intron_variant Intron 16 of 17

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ALKENST00000389048.8 linkc.2763C>T p.Phe921Phe synonymous_variant Exon 16 of 29 1 NM_004304.5 ENSP00000373700.3
ALKENST00000618119.4 linkc.1632C>T p.Phe544Phe synonymous_variant Exon 15 of 28 5 ENSP00000482733.1

Frequencies

GnomAD3 genomes
AF:
0.000178
AC:
8
AN:
45068
Hom.:
0
Cov.:
0
show subpopulations
Gnomad AFR
AF:
0.000166
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000672
Gnomad SAS
AF:
0.00362
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000495
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000771
AC:
13
AN:
168570
AF XY:
0.0000537
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000588
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000188
Gnomad FIN exome
AF:
0.000120
Gnomad NFE exome
AF:
0.0000357
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000163
AC:
74
AN:
453882
Hom.:
0
Cov.:
14
AF XY:
0.000192
AC XY:
46
AN XY:
239714
show subpopulations
⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
0.00
AC:
0
AN:
11174
American (AMR)
AF:
0.000174
AC:
4
AN:
22964
Ashkenazi Jewish (ASJ)
AF:
0.000173
AC:
2
AN:
11560
East Asian (EAS)
AF:
0.0000543
AC:
1
AN:
18402
South Asian (SAS)
AF:
0.000454
AC:
19
AN:
41806
European-Finnish (FIN)
AF:
0.000128
AC:
4
AN:
31348
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
2662
European-Non Finnish (NFE)
AF:
0.000140
AC:
41
AN:
293088
Other (OTH)
AF:
0.000144
AC:
3
AN:
20878
⚠️ The allele balance in gnomAD4 Exomes is highly skewed from 0.5 (p-value = 0.000000000000000222045), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.368
Heterozygous variant carriers
0
4
8
13
17
21
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000177
AC:
8
AN:
45154
Hom.:
0
Cov.:
0
AF XY:
0.000225
AC XY:
5
AN XY:
22250
show subpopulations
African (AFR)
AF:
0.000165
AC:
2
AN:
12124
American (AMR)
AF:
0.00
AC:
0
AN:
5002
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
1012
East Asian (EAS)
AF:
0.000673
AC:
1
AN:
1486
South Asian (SAS)
AF:
0.00363
AC:
4
AN:
1102
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
3312
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
68
European-Non Finnish (NFE)
AF:
0.0000495
AC:
1
AN:
20214
Other (OTH)
AF:
0.00
AC:
0
AN:
570
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.463
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0

ClinVar

Significance: Likely benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Benign:2
Mar 29, 2022
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Feb 15, 2022
Sema4, Sema4
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Neuroblastoma, susceptibility to, 3 Benign:1
Dec 04, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.30
CADD
Benign
15
DANN
Benign
0.78
PhyloP100
4.9
Mutation Taster
=32/68
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs201042802; hg19: chr2-29451802; COSMIC: COSV101202336; COSMIC: COSV101202336; API